Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold

Reports

6

Domains carrying it

6

First reported

24 August 2026

Latest report

24 August 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 24 August 2026FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndromereuters.com
2. 24 August 2026RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ...es.tradingview.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• Dr Reddy's wins FDA nod for rituximab biosimilar5 reports · 5 domains · 14 August 2026
• How Investors Are Reacting To Replimune Group (REPL) FDA Accelerated Approval For ...4 reports · 4 domains · 10 August 2026
• Labcorp's advanced melanoma CDx secures FDA approval3 reports · 3 domains · 10 August 2026
• Scholar Rock: FDA Grants Fast Track And Orphan Drug Designations To Apitegromab2 reports · 2 domains · 3 September 2026
• FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients2 reports · 2 domains · 28 August 2026
• Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of ...2 reports · 2 domains · 31 August 2026

◆ Share

◆ Evidence

6 reports · 6 domains

• RGNX Stock On Track For Worst Day In Over Three Months — BofA Says Buy Despite ...es.tradingview.com · 24 August 2026
• Regenxbio Delays Hunter Syndrome Gene Therapy Plans After FDA Clinical Holdprecisionmedicineonline.com · 24 August 2026
• REGENXBIO Announces Regulatory Update on RGX-121 for MPS IIprnewswire.com · 24 August 2026
• Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Holdtradingview.com · 24 August 2026
• Regenxbio gene therapy refiling plan derailed by FDA holdfiercebiotech.com · 24 August 2026
• FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndromereuters.com · 24 August 2026